Effect of Bupleurum falcatum on the stress-induced impairment of spatial working memory in rats

Biological and Pharmaceutical Bulletin

Volumn 32, Issue 8, 2009, Pages 1392-1398

  Lee, Bombi ^a   Shim, Insop ^b   Lee, Hyejung ^a   Hahm, Dae Hyun ^a  

^a Kyung Hee University   (South Korea)

^b The Catholic University of Korea   (South Korea)

Author keywords

Bupleurum falcatum; Choline acetyltransferase; Elevated plus maze; Morris water maze; Stress

Indexed keywords

ACETYLCHOLINESTERASE; BUPLEURUM FALCATUM EXTRACT; BUPLEURUM ROOT EXTRACT; CHOLINE ACETYLTRANSFERASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; ATTENUATION; BUPLEURUM; CHOLINERGIC SYSTEM; CONTROLLED STUDY; DRUG MECHANISM; ELEVATED PLUS MAZE TEST; ENZYME ACTIVITY; ESCAPE BEHAVIOR; EXPOSURE; HIPPOCAMPUS; IMMOBILIZATION STRESS; IMMUNOREACTIVITY; LATENT PERIOD; LEARNING; MALE; MAZE TEST; MEDICINAL PLANT; MEMORY DISORDER; MORRIS WATER MAZE TEST; NERVE CELL; NEUROPROTECTION; NONHUMAN; RAT; SPATIAL MEMORY; TRANQUILIZING ACTIVITY; WORKING MEMORY;

ACETYLCHOLINESTERASE; ANIMALS; BUPLEURUM; CHOLINE O-ACETYLTRANSFERASE; DRUGS, CHINESE HERBAL; HIPPOCAMPUS; IMMUNOHISTOCHEMISTRY; MALE; MAZE LEARNING; MEMORY DISORDERS; MEMORY, SHORT-TERM; RATS; RATS, SPRAGUE-DAWLEY; RESTRAINT, PHYSICAL; SPATIAL BEHAVIOR; STRESS, PSYCHOLOGICAL;

EID: 69149091474     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.32.1392     Document Type: Article

References (59)

1. Selye H., Am. Sci., 61, 692-699 (1973).
2. Kim J. J., Lee H. J., Welday A. C., Song E., Cho J., Sharp P. E., Jung M. W., Blair H. T., PNAS, 104, 18297-18302 (2007).
3. MeEwen B. S., Sapolsky R. M., Curr. Opin. Neurobiol., 5, 205-216 (1995).
4. Kim J. J., Diamond D. M., Nat. Rev. Neurosci.., 3, 453-462 (2002).
5. Joels M., Pu Z., Wieqert O., Oitzl M. S., Kruqers H. J., Trends Cogn. Sci., 10, 152-158 (2006).
6. Oh J. K., Kim Y. S., Park H. J., Lim E. M., Pyun K. H., Shim I., Biol. Pharm. Bull., 30, 1422-1426 (2007).
7. Cook S. C., Wellman C. L., J. Neurobiol., 60, 236-248 (2004).
8. Galea L. A., McEwen B. S., Tanapat P., Deak T., Spencer R. L., Dhabhar F. S., Neuroscience, 81, 689-697 (1997).
9. Magarinos A. M., McEwen B. S., Flugge G., Fuchs E., J. Neurosci., 16, 3534-3540 (1996).
10. Woolley C. S., Gould E., McEwen B. S., Brain Res., 531, 225-231 (1990).
11. Luine V., Villegas M., Martinez C., McEwen B. S., Brain Res., 639, 167-170 (1994).
12. Shors T. J., Seib T. B., Levine S., Thompson R. F., Science, 244, 224-226 (1989).
13. McEwen B., Front. Neuroendocrinol., 20, 49-70 (1990).
14. Umegaki H., Yamamoto A., Suzuki Y., Iguchi A., Neuro. Endocrinol. Let., 27, 339-343 (2006).
15. Kaufer D., Friedman A., Seidman S., Soreq H., Chem. Biol. Interact., 14, 349-360 (1999).
16. Armstrong D. M., Saper C. B., Levey A. I., Wainer B. H., Terry R. D., J. Comp. Neurol., 216, 53-68 (1983).
17. Flicker C., Dean R. L., Watkins D. L., Fisher S. K., Bartus R. T., Pharmacol. Biochem. Behav., 18, 973-981 (1983).
18. Bederson J. B., Pitts L. H., Tsuji M., Nishimura M. C., Davis R. L., Bartkowski H., Stroke, 17, 472-476 (1986).
19. Nilsson O. G., Leanza G., Rosenblad C., Lappi D. A., Wiley R. G., Bjorklund A., Neuroreport, 3, 1005-1008 (1992).
20. Kim M. S., Kwon D. Y., Cho H. J., Lee M. S., Phytother. Res., 20, 235-236 (2006).
21. Sun X. B., Matsumoto T., Yamada H., J. Pharm. Pharmacol., 43, 699-704 (1991).
22. Takagi K., Shibata M., Yakugaku Zasshi, 89, 1367-1378 (1969).
23. Tani T., Katsuki T., Kubo M., Arichi S., J. Chromatogr., 360, 407-416 (1986).
24. Takagi K., Shibata M., Yakugaku Zasshi, 89, 712-720 (1996).
25. Xie W., Li C. Z., Bao Y., Yu L. J., Nan Fang Yi Ke Da Xue Xue Bao, 26, 1132-1135 (2006).
26. Henry M. E., Schmidt M. E., Hennen J., Villafuerte R. A., Butman M. L., Tran P., Kerner L. T., Cohen B., Renshaw P. F., Neuropsychopharmacology, 30, 1576-1583 (2005).
27. Avital A., Richter-Levin G., Leschiner S., Spanier I., Veenman L., Weizman A., Gavish M., Neuropsychopharmacology, 25, 669-678 (2001).
28. Paxinos G., Watson C., "The Rat Brain in Stereotaxic Coordinates," Academic Press, New York, 1986.
29. Abe H., Sakaguchi M., Yamada M., Arichi S., Odashima S., Planta Med., 40, 366-372 (1980).
30. Morris R. G., Garrud P., Rawlins J. N., O'Keefe J., Nature (London), 297, 681-683 (1982).
31. Arnsten A. F., Prog. Brain Res., 126, 183-192 (2000).
32. Mizoguchi K., Yuzurihara M., Ishige A., Sasaki H., Chui D.-H., Tabira T., J. Neurosci., 15, 1568-1574 (2000).
33. Radley J. J., Sisti H. M., Rocher A. B., Hao J., McCall T., Hof P. R., McEwen B. S., Morrison J. H., Neuroscience, 125, 1-6 (2004).
34. Nakade Y., Mantyh C., Pappas T. N., Takahashi T., J. Gastroenterol., 42, 279-282 (2007).
35. Padovan C. M., Guimaraes F. S., Braz. J. Med. Biol. Res., 33, 79-83 (2000).
36. Zurita A., Martijena I., Cuadra G., Brandao M. L., Molina V., Behav. Brain Res., 20, 163-171 (2000).
37. Rodgers R. J., Dalvi A., Neurosci. Biobehav., 21, 801-810 (1997).
38. Pellow S., Chopin P., File S. E., Briley M., J. Neurosci. Methods, 14, 149-167 (1985).
39. Wright I. K., Upton N., Marsden C. A., Psychopharmacology, 109, 338-346 (1992).
40. Padovan C. M., Guimaraes F. S., Braz. J. Med. Biol. Res., 33, 79-83 (2000).
41. Poirier M. F., Boyer P., Br. J. Psychiatry, 175, 12-16 (1999).
42. Das A., Kapoor K., Sayeepriyadarchini A. T., Dikshit M., Palit G., Nath C., Pharmacol. Res., 42, 213-217 (2000).
43. Anisman H., Kokkinidis I., Sklar L. S., "Theory in Psychopharmacology," Academic Press, London, 1981, pp. 65-102.
44. Helper D. J., Olton D. S., Wenk G. I., Coyle J. T., J. Neurosci., 5, 866-873 (1985).
45. Nabeshima T., Ogawa S., Nishimura H., Fuji K., Kameyama T., Sasaki Y., J. Pharmacol. Exp. Therap., 45, 81-87 (1991).
46. Aigren T. G., Mishkin M., Behav. Neural. Biol., 45, 81-87 (1986).
47. Ito J., Nabeshima T., Kameyama T., Psychopharmacology, 101, 27-33 (1990).
48. Cooper J. R., Bloom F. E., Roth R. H., "Acetylcholine, The Biochemical Basis of Neuropharmacology," Oxford University Press, New York, 2003.
49. Eichenbaum H., Science, 277, 330-332 (1997).
50. Milner B., Squire L. R., Kandel E. R., Neuron, 20, 445-468 (1998).
51. Redrobe R. D., Dumont Y., Fournier A., Quirion R., Neuropsychopharmacology, 26, 615-624 (2002).
52. Serra M., Concas A., Mostallino M. C., Chessa M. F., Stomati M., Petraglia F., Genazzani A. R., Biggio G., Psychoneuroendocrinology, 24, 269-284 (1999).
53. Sweerts B. W., Jarrott B., Lawrence A. J., J. Neuroendocrinol., 13, 608-617 (2001).
54. Carrasco G. A., Van de Kar L. D., Eur. J. Pharmacol., 463, 235-272 (2003).
55. Sainsbury A., Rohner-Heanrenaud F., Cusin I., Zakrzewska K. E., Halban P. A., Gaillard R. C., Jeanrenaud B., Diabetologia, 40, 1269-1277 (1997).
56. Mizoguchi K., Sun N., Jin X. L., Kase Y., Takeda S., Maruyama W., Tabira T., Pharmacol. Biochem. Behav., 86, 55-61 (2007).
57. Mizoguchi K., Yuzurihara M., Ishige A., Aburada M., Tabira T., Pharmacol. Biochem. Behav., 75, 419-425 (2003).
58. Chen S. W., Min L., Li W. J., Kong W. X., Li J. F., Zhang Y. J., Pharmacol. Biochem. Behav., 79, 377-382 (2004).
59. Liu T. P., Liu M., Tsai C. C., Lai T. Y., Hsu F. L., Cheng J. T., J. Pharm. Pharmacol., 54, 681-688 (2002).